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Background: DNA damage response has been clearly described as an anti-cancer barrier in early human
tumorigenesis. Moreover, interestingly, testicular germ cell tumors (TGCTs) have been reported to lack the DNA
Damage Response (DDR) pathway activation.
CCDC6 is a pro-apoptotic phosphoprotein substrate of the kinase ataxia telangectasia mutated (ATM) able to
sustain DNA damage checkpoint in response to genotoxic stress and is commonly rearranged in malignancies
upon fusion with different partners.
In our study we sought to determine whether CCDC6 could have a role in the patho-genesis of testicular germ cell
tumors.
Methods: To achieve this aim, analysis for CCDC6 expression has been evaluated on serial sections of the mouse
testis by immunohistochemistry and on separate populations of murine testicular cells by western blot. Next, the
resistance to DNA damage-induced apoptosis and the production of reactive oxygen species has been investigated
in GC1 cells, derived from immortalized type B murine germ cells, following CCDC6 silencing. Finally, the CCDC6
expression in normal human testicular cells, in Intratubular Germ Cell Neoplasia Unclassified (IGCNU), in a large
series of male germ cell tumours and in the unique human seminoma TCam2 cell line has been evaluated by
immunohistochemistry and by Western Blot analyses.
Results: The analysis of the CCDC6 expression revealed its presence in Sertoli cells and in spermatogonial cells.
CCDC6 loss was the most consistent feature among the primary tumours and TCam2 cells. Interestingly, following
treatment with low doses of H2O2, the silencing of CCDC6 in GC1 cells caused a decrease in the oxidized form of
cytochrome c and low detection of Bad, PARP-1 and Caspase 3 proteins. Moreover, in the silenced cells, upon
oxidative damage, the cell viability was protected, the γH2AX activation was impaired and the Reactive Oxygen
Species (ROS) release was decreased.
Conclusions: Therefore, our results suggest that the loss of CCDC6 could aid the spermatogonial cells to be part of
a pro-survival pathway that helps to evade the toxic effects of endogenous oxidants and contributes to testicular
neoplastic growth.
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Testicular germ cell tumours (TGCTs), the most com-
mon malignancy in males aged 15–34 years, represent a
major cause of death attributable to cancer in this age
group [1,2]. TGCTs can be subdivided into seminoma
and non-seminoma germ cell tumours (NSGCTs), in-
cluding embryonal cell carcinoma, choriocarcinoma, yolk
sac tumour and teratoma. Neoplasms containing more
than one tumour cell component, eg seminoma and em-
bryonal cell carcinoma, are referred to as mixed germ cell
tumours. Seminomas and NSGCTs present distinctive
clinical features with significant differences in prognosis
and therapeutic approach [3]. Nevertheless, the molecu-
lar alterations and biomarkers of TGCTs still remain
poorly defined [4]. Recently, it has been suggested that
resistance to oxidative DNA damage is commonly associ-
ated to testicular germ cell transformation [5].
The maintenance of the genome integrity and the pro-
tection against the harmful mutagenic effects of DNA
damage rely on the DNA damage response (DDR) ma-
chinery postulated to serve as an inducible barrier against
tumorigenic transformation and/or progression for hu-
man cancers [6,7]. Notably, testicular germ cell tumours
have been shown, so far, to represent an exception among
human malignancies tested for constitutive DDR activa-
tion in that this phenomenon occurs only rarely [8].
In previous works we have documented the CCDC6
gene product as a pro-apoptotic protein substrate of
ATM, able to sustain DNA damage checkpoints in re-
sponse to DNA damage [8-10]. CCDC6 was originally
identified upon rearrangement with RET in thyroid and
lung tumours [11,12], and with genes other than RET in
solid and not solid tumours [13-16]. In most cancers
harbouring CCDC6 gene rearrangements, the product of
the normal allele is supposed to be functionally impaired
or absent. Fusions including CCDC6 or other genes have
not been reported in TGCTs, so far (www.sanger.ac.uk/
genetics/CGP/cosmic). Recently, the finding that CCDC6
helps to protect genome integrity by modulating PP4C
activity directed towards pS139_H2AX dephosphoryla-
tion following DNA damage [11], makes CCDC6 an at-
tractive candidate that could help pre-cancerous cells
overcome a DNA damage response-dependent barrier
against tumour progression. Therefore, we hypothesize
that, when CCDC6 is deleted or silenced, the loss of
checkpoints and of repair accuracy [17] might favour
genome instability and may represent an early independ-
ent event of a multistep carcinogenetic process in pri-
mary tumours.
The tissue distribution and cell type-related expres-
sion patterns of CCDC6 in normal tissue remain
largely unknown; on the other hand there are as yet
no reports of analyses of CCDC6 in either human or
animal tumours.By the analysis of the Gene Expression Atlas (Array
ExpressAtlas), a meta-analysis-based database of the
ArrayExpress Archive, we noticed that CCDC6 was pre-
dicted as downregulated in germ cell tumours. Here, we
intend to gain more insights into the CCDC6 tissue biol-
ogy and its relation to testicular cancer in order to unravel
a role for CCDC6 as a new DDR component that partici-
pates in genome stability maintenance and whose mal-
function may contribute to the pathogenesis of germ cell
tumours.
Methods
Cell lines and antibodies
The GC-1 cell line was cultured in Dulbecco’s modified
Eagle’s medium (D-MEM) supplemented with 10% fetal
bovine serum (FBS; Gibco BRL, Italy) and grown in a 37°C
humidified atmosphere of 5% CO2 [18]. TCAM-2 cells
were grown at 37°C in a 5% CO2 atmosphere in RPMI
1640 (Lonza) supplemented with 10% FBS [19]. Anti
pS139_H2AX antibody was from Millipore; Anti-H2AX,
anti-pT68Chk2 and anti-Chk2 antibodies were from Cell
Signaling Technology, Inc; anti MDC1 and anti CCDC6
were from Abcam; Anti-Cytochrome c (Biovision Inc,
USA); anti COX IV (Cell Signaling Technology, Inc);
Anti-Caspase 3 (H-277) Sc 7148, anti-Bcl 2 (N19) Sc 492,
anti-PARP (H250) Sc 7150, anti-Bad (C20) Sc493 and sec-
ondary antibodies were from Santa Cruz Biotechnology,
Inc; Anti α-tubulin was from Sigma -Aldrich Co. LLC.
Plasmids and transfections
Mission shRNA (pLKO.1 puro) were from Sigma-Aldrich,
Co. LLC.
For transient transfection assays the GC1 cells were trans-
fected with the plasmid pool (shCCDC6, NM_001111121.1)
or a pool of non- targeting vectors (sh control) by the Nuc-
leofector transfection system. pCDNA4TO-CCDC6T434A
mutant has been described elsewhere [10]. The Fugene
reagent (Roche Ltd, Basel, Switzerland) was used to
transfect GC1 cells accordingly to the manufacturer’s
instructions.
MTT cell proliferation assay
GC-1 cells were transfected with mission shCCDC6 or a
control non-targeting scrambled sh, after 48h were treated
with H2O2 at different doses (range of 1, 2, 5 and 10 μM)
for 1h, as indicated. After washing out the hydrogen per-
oxide we have left the cells an additional hour before pro-
cessing them. 20 ml of Promega’s CellTiter 96 AQueous
One Solution (Promega) were then dispensed into each
well and absorbance at 595 nm was measured to evaluate
cell viability. Data reported are the average +/− s.d. of
three independent experiments performed in sextuplicate.
Anti-proliferative assays with a wide range of H2O2 doses
(1, 2, 5, 10 and 50 μM) and at different times (30 min and
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shCtrl), are shown in the Additional file 1: Figure S1. Data
reported are the average +/− s.d. of three independent
experiments performed in sextuplicate.
Apoptosis assays
GC-1 cells were transfected with mission shCCDC6 or a
control non-targeting scrambled sh, after 48 h this cells
were treated with H2O2 at 10 μM for 1 h and apoptosis
was quantified by measuring Caspase 3/7 activation using
the Caspase-Glo 3/7 assay (Promega) according to the
manufacturer’s instructions.
Cytochrome c releasing apoptosis assay Kit
GC-1 cells were transfected with mission shCCDC6 or a
control non-targeting scrambled sh, after 48 h of transfec-
tion the apoptosis was induced by treatment of cells with
H2O2 at 10 μM. After 1 h of H2O2 treatment, the cyto-
chrome c release was quantified using the Cytochrome c
Releasing Apoptosis Assay Kit (BioVision Inc, USA)
according to the manufacturer’s instructions.
Preparation of testicular cells
Germ cells were prepared from testes of adult CD1 mice
(Charles River Italia). Testes were freed from the
albuginea membrane and digested for 15 min in 0.25%
(w/v) collagenase (type IX, Sigma) at room temperature
under constant shaking. They were then washed twice in
minimum essential medium (Life Technologies, Inc.),
seminiferous tubules were cut into pieces with a sterile
blade and further digested in minimum essential medium
containing 1 mg/ml trypsin for 30 min at 30°C. Digestion
was stopped by adding 10% fetal calf serum and the germ
cells released were collected after sedimentation (10 min
at room temperature) of tissue debris. Germ cells were
centrifuged for 13 min at 1500 r.p.m. at 48°C and the
pellet resuspended in 20 ml of elutriation medium (120.1
mM NaCl, 4.8 mM KCl, 25.2 mM NaHCO3, 1.2 mM
MgS4 (7H2O), 1.3 mM CaCl2, 1.1 mM glucose, 1X
essential amino acid (Life Technologies, Inc.), penicillin,
streptomycin, 0.5% bovine serum albumin). Pachytene
spermatocyte and spermatid germ cells were obtained by
elutriation of the unfractionated single cell suspension.
Homogeneity of cell populations ranged between 80 and
85% (pachytene spermatocytes) and 95% (spermatids),
was routinely monitored morphologically. Spermatogonia
were obtained from prepuberal mice as previously de-
scribed [20]. Mature spermatozoa were obtained from
the cauda of the epididymis of mature mice as described
previously [21].
TMA building
According to ethical guidelines, Tissue Micro-Array
(TMA) was built using the most representative areasfrom each single case. All tumours and controls were
reviewed by two experienced pathologists. Discrepancies
between two pathologists from the same case were re-
solved in a joint analysis of the cases. Tissue cylinders
with a diameter of 0.3 mm were punched from morpho-
logically representative tissue areas of each ‘donor’ tissue
block and brought into one recipient paraffin block
(3×2.5 cm) using a semiautomated tissue arrayer (Galileo
TMA, Milan, Italy).
Histological analysis and immunohistochemistry
For light microscopy, tissues were fixed by immersion in
10% formalin and embedded in paraffin by standard pro-
cedures; 4 μm sections were stained with haematoxylin
and eosin (H&E) or processed for immunohistochemistry.
The classical avidin–biotin peroxidase complex (ABC)
procedure was used for immunohistochemistry. The sec-
tions were incubated overnight with antibodies against
CCDC6 at 1: 200 dilution. The following controls were
performed: (a) omission of the primary antibody; (b) sub-
stitution of the primary antiserum with non-immune
serum diluted 1: 500 in blocking buffer; (c) addition of the
target peptide used to produce the antibody (10−6 M); no
immunostaining was observed after any of the control
procedures. The antibody against the CCDC6 proteins is
from Sigma-Aldrich, Co. LLC. (HPA-019051).
Protein extraction and western blot analysis
Total cell extracts (TCE) were prepared with lysis buffer
(50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% Triton
X-100, 0.5% Na Deoxycholate, 0.1% SDS) and a mix of
protease inhibitors. Protein concentration was estimated
by a modified Bradford assay (Bio-Rad). Total proteins
were prepared as described [22]. Membranes were
blocked with 5% TBS-BSA proteins and incubated with
the primary antibodies. Immunoblotting experiments
were carried out according to standard procedures and
visualized using the ECL chemiluminescence system
(Amersham/Pharmacia Biotech). As a control for equal
loading of protein lysates, the blotted proteins were
probed with antibody against anti-γ-tubulin protein.
Real time PCR
Total RNA was isolated using TRI-reagent solution
(Sigma) according to the manufacturer’s instructions and
treated with DNase I (GenHunter Corporation, Nashville,
TN, U.S.A.). RNA (1 μg) was reverse-transcribed using a
mixture of poly-dT and random exonucleotides as primers
and MuLV RT (PerkinElmer, Boston, MA, U.S.A.). PCR
reverse transcription was performed according to standard
procedures (Qiagen). qRT-PCR analysis was performed
using the follows primers annealing at CCDC6 amino-
terminus: Fw: ggagaaagaaacccttgctg and Rv: tcttcatcagtttg
ttgacctga. To calculate the relative expression levels we
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used for normalization of qRT-PCR data [23].Fluorometric determination of Reactive Oxygen
Species (ROS)
The production of ROS was measured using the
5,6-carboxy-2′-7′-dichlorofluorescein-diacetate, DCFH-DA,
fluorometric method, which is based on the ROS-
dependent oxidation of DCFH-DA to DCF (Molecular
Probes, The Netherlans). Control and transfected GC1
cells, after H2O2 exposure where indicated, were treated
with DCFH-DA (20 μM) for 30 min at 37°C in the dark.
Intracellular ROS production was measured with a spec-
trofluorometer (SFM 25; Kontron Instruments, Japan). A
positive control was obtained by incubating GC1 cells
with H2O2 at 10 μM for 1 hour.Figure 1 CCDC6 expression in adult mouse testis.
(A) Immunohistochemical staining for CCDC6 protein in adult
mouse testis (LSAB tecnique). A representative seminiferous tubule
showing staining in the basal germ cells (arrow heads), Sertoli cells
and Leydig cells. (B) Distribution of CCDC6 protein in mouse
testicular cells. Western blot analysis of CCDC6 protein in mouse
adult testis (lane 1), interstitium (lane 2), Sertoli cells (lane 3) and
normal mouse germ cells (lanes 4–7) (40 μg/lane). Whole lysates
were detected by western blotting with anti-CCDC6 polyclonal
serum or with anti-ERK1 antibodies used as an internal standard.
ERK1 antibodies recognize both ERK1 and ERK2, which are expressed
at similar levels in all cell types with the exception of spermatozoa.
Anti-tubulin hybridization is shown as loading control.Results
CCDC6 expression in mouse testicular cells
In order to define the cells in which CCDC6 is expressed
in the normal testis, immunohistochemical analysis for
this protein was performed on serial sections of the
mouse testis. The CCDC6 protein was widely expressed
in the germinal epithelium, mostly in the spermatogonial
cells found at the basal compartment of the seminiferous
epithelium, where they adhere to the basement mem-
brane, while less so in the spermatocytes and spermatids.
The Sertoli cells, essential components of the niche
where they physically support the spermatogonial cells
and provide them with growth factors, also expressed a
good amount of the CCDC6 gene product, while it was not
detectable in the spermatozoa (Figure 1A). Importantly, we
checked that the antiserum used in this study fulfilled the
criteria of specificity. In particular, immunoadsorption
tests revealed that the labeling was totally blocked by
preincubation of the antibody with 10-6 M of the cognate
peptide (data not shown).
Next, we confirmed the differential expression of
CCDC6 in the different cell types in the mouse testis,
by Western Blot analysis of cell extracts from the
adult mouse testis fractionated in interstitial, Sertoli,
spermatogonia, spermatocytes, spermatids and sperm-
atozoa. Immunoblot analysis performed on cell types
enriched in the different types of germ cells showed a
single product migrating as a 65 kDa protein (Figure 1B).
Among germ cells, CCDC6 was well expressed in the
spermatogonia, less abundant in the spermatocytes and
spermatids and absent in the spermatozoa (Figure 1B),
in agreement with the immunohistochemical results.
Moreover, the CCDC6 protein was present in the inter-
stitial, at low levels, and the Sertoli extract cells
(Figure 1B).CCDC6 silencing in the GC-1 spermatogonia increases the
resistance to peroxide-induced apoptosis
We have previously reported that CCDC6 overexpression
is able to induce apoptosis [9]. Conversely, we have shown
that several CCDC6 mutants or CCDC6 depletion
protected cell viability from multiple and diverse apoptotic
stimuli [9,10]. Recently, it has been reported that primary
testicular germ cells are prone to apoptosis at very low
concentrations of H2O2 [24]. Next, we investigated
CCDC6 expression in the GC1 cells, derived from immor-
talized type B murine germ cells that were found to ex-
press good levels of CCDC6 (Figure 2A, right). In order to
investigate if the loss of CCDC6 could affect hydrogen
peroxide-induced apoptosis in CCDC6-expressing primor-
dial GC1 cells, we silenced its expression by the transient
transfection of specific shRNAs directed against murine
CCDC6 and exposed the cells to different doses of hydro-
gen peroxide for 1 hour (Figure 2A, right). We observed a
reversion of an antiproliferative effects following hydrogen
peroxide exposure in CCDC6 silenced- compared to con-
trol GC1 cells. (Figure 2A, left). Pro-apoptotic stimuli, like
reactive oxygen species (ROS), are able to activate the
Figure 2 Peroxide sensitivity in CCDC6 silenced GC1 cells. (A) Left side: percentage of cell viability evaluated by MTT analysis on GC1
shCCDC6 or sh ctrl cells not treated or treated for 1 hour with H2O2. Right side: CCDC6 and Cytochrome C immunoblots of GC1 shCCDC or sh
ctrl cells, not treated or treated with H2O2. (B) Protein extracts from cytosol (C) and mitochondria (M) of shctrl and shCCDC6 cells untreated or
treated with H2O2 as indicated were assayed for Cytochrome c by western blot analysis. Tubulin was used as cytosolic marker and COX IV as a
mitochondrial marker. Densitometric acquisition are shown from three separate experiments. *p > 0,05 vs untreated shCTRL and shCCDC6 cells
(C) WB analysis from GC1 shCCDC6 or sh ctrl lysates from cells not treated or treated with H2O2. The blots are representative of three
independent experiments. (D) Caspase 3 activity was evaluated in GC1 cells, shCCDC6 or sh ctrl, not treated or treated with H2O2. The plotted
values represent the mean +/- s.e.m. of three independent experiments. (E) Whole cell lysates from GC1 shCCDC6 or sh ctrl cells, and from GC1
cells overexpressing CCDC6T434A or the empty vector, treated with H2O2 (10 μM) or untreated were immunoblotted with anti-CCDC6 or anti-
myc. Anti- γH2AX and total H2AX are shown. (F) GC1 cells, depleted or not depleted for CCDC6, were exposed to 50 μM H2O2 for 30 minutes
and ROS intracellular levels were evaluated by the DCFH-DA fluorometric method. (G) GC1 cells overexpressing CCDC6T434A or the empty
vector were exposed to 50 μM H2O2 for 30 minutes and ROS intracellular levels were evaluated by the DCFH-DA fluorometric method. In F and
G data are representative of three separate experiments. # p > 0.05 vs control. Immunoblot of anti-tubulin is shown in A, C and E.
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membrane permeabilization and the release of cyto-
chrome c in the cytosol [25]. Indeed, by western blot ana-
lysis, we observed that the oxidized form of cytochrome c
was significantly decreased in GC1-shCCDC6, compared
to controls (Figure 2A, right). Furthermore, we performed
the Cytochrome C Releasing Apoptosis Assay that we
show in Figure 2B. By this assay we found that 48 hours
after the transient silencing of shCCDC6 and shCTRL in
GC1 cells the cytochrome c release in the cytosol of the
GC1 shCCDC6 cells showed a slightly increase, compared
to the significant high levels detected in the shCTRL GC1
cells, following one hour exposure to 10 μM H2O2, after
washing out the hydrogen peroxide and leaving the cells
an additional hour before the lysis. The same filters were
reprobed with a monoclonal antibody against cytochrome
oxidase subunit IV (COX IV) which is a mitochondrial
marker, and then with the anti-tubulin antibody, which is
a cytosolic marker. The absence of COX IV in the cyto-
solic samples confirmed the absence of mitochondrial
contamination in the cytosolic fractions (Figure 2B, left).
Finally we sorted out the relative intensity of the cyto-
chrome c in the cytosolic and mitochondrial fractions nor-
malized against the tubulin and the COX IV markers,
respectively, in shctrl and in sh CCDC6 GC1 cells, by
densitometric analyses of three independent experiments
(Figure 2B, right).
To determine whether the H2O2-induced redox imbal-
ance and the subsequent GC1 cell apoptosis were associ-
ated with changes in pro- and anti-apoptotic proteins, the
expression of these proteins was analyzed by western blot.
Bad protein showed lower levels in the GC1-shCCDC6
transfected cells compared to the sh-control transfected
cells, after 1 hour treatment with 10 μM H2O2. The anti-
apoptotic Bcl2 protein levels were found to be increased
after 10 μM hydrogen peroxide treatment in the CCDC6-
depleted GC1 cells, compared to the CCDC6-proficient
cells. In addition, we observed that the levels of Caspase 3
and of the cleaved PARP-1 proteins were reduced in the
CCDC6-silenced cells compared to the controls. In these
experiments, the effects were more evident at 10 μM than
at 1, 2 and 5 μM doses of H2O2, according to the
efficiency of the transient silencing (Figure 2C; Additional
file 2: Figure S2). To investigate whether CCDC6 silencing
was able to confer protection by H2O2 induced apoptosis
in testicular germ cells, we studied caspase −3 activity. We
found that caspase −3 activity was reduced in shCCDC6
compared to shCTRL GC1 cells, upon 10 μM H2O2
treatment for 1 hour (Figure 2D).
CCDC6 silencing in the GC-1 germ cells decreases reactive
oxygen species production
We reported that stable CCDC6 depletion in HeLa cells
affected the phosphorylation of histone H2AX on S139,upon IR and etoposide exposure [11]. In the same cells,
CCDC6 silencing affects the levels of histone H2AX phos-
phorylation, upon H2O2 treatment (data not shown).
Interestingly, in the stable CCDC6-interfered HeLa cells,
the re-expression of the wild type protein but not of the
CCDC6 protein mutated in the T434A residue, an ATM
kinase phosphorylation target, restored pS139_H2AX
levels in response to genotoxic stress [11]. Indeed, also in
the GC1 cells, the transient silencing of CCDC6 impaired
pS139_H2AX detection upon low doses of H2O2 treat-
ment, compared to control cells (Figure 2E). Notably, the
overexpression of the CCDC6 T434A mutant, that be-
haved as a dominant negative of the wild type protein, af-
fected the phosphorylation status of the histone H2AX in
the absence or presence of H2O2, in comparison to the
empty vector transfected cells (Figure 2E). These observa-
tions therefore suggested that the recognition site for the
ATM kinase in CCDC6 was also important in response to
DNA damage induced by oxidative stress. By immunoblot
analysis of CCDC6, we could also observe that the protein
was stabilized in response to H2O2 in the sh-ctrl and in
the empty vector transfected GC-1 cells, compared to the
T434A overexpressing cells, where the H2O2 treatments
did not stabilize the CCDC6 protein (Figure 2E). As a con-
trol, in the lanes where CCDC6 was silenced in the GC1
cells (−/+H2O2), the anti-CCDC6 hybridization allows a
verification of the efficiency of the silencing (Figure 2E).
Overall, these experiments have showed that, in the GC1
cells, the loss of CCDC6 or its functional impairment by
mutation of a single residue limited the amount of
S139_pH2AX that then influenced the sensing of DNA
damage induced by H2O2, relative to the control cells.
Finally, to evaluate whether an altered redox state could
be responsible for the pro-survival effects observed when
CCDC6 is depleted, we measured the intracellular levels
of ROS, in response to H2O2 exposure. In the GC1 cells
the transient silencing of CCDC6 produced lower levels of
ROS, compared to control (*p ≤ 0.05) (Figure 2F), as
judged by the fluorescence signal detection following the
interaction between the DCFH-DA probe and ROS. In the
same cells, the transient expression of the mutant CCDC6
T434A counteracted the ROS production, compared to
the control (# p ≤ 0.05) (Figure 2G).
CCDC6 and DDR protein expression in testicular
seminomas
In order to assess the CCDC6 expression in human testes
and testicular germ cell tumors, in the first instance we
tested twenty testicular seminomas, including IGCNU,
one yolk salk tumor and five embrionary carcinomas and
the corresponding normal tissues for CCDC6 expression
by immunohistochemistry with an anti-CCDC6 specific
monoclonal antibody. The representative immunohisto-
chemical stainings are shown in Figure 3. CCDC6 was
Figure 3 Immunohistochemical staining for CCDC6 in human
testis. Immunohistochemical staining for CCDC6 in normal testis,
normal testis adjacent to an area of seminoma, IGCNU (intratubular
germ cell neoplasia unclassified), seminoma (top to bottom), yolk sac
tumor and embyonary carcinoma. Immunoreactivity for CCDC6 is mainly
detected in nuclei of primordial germinal cells and Sertoli cells of normal
testis; nuclear CCDC6 reactivity is almost absent in IGCNU, in seminoma,
in yolk sac tumour and in embryonal carcinoma. Magnifications are
respectively: 200×, 106×, 250×, 250×, 250×, 250×.
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neoplastic cells in the seminomas. In the testicular tissues
adjacent to the tumour, normal or atrophic and not af-
fected by neoplastic transformation, it was possible to ap-
preciate the CCDC6 positivity mainly in the nucleus of
the spermatogonial cells identified, on the basis of the
morphological features, at the basal layer of the tubules.
The CCDC6 staining decreased proceeding from the basal
layer to the lumen (Figure 3). The Sertoli and Leydig cells
showed both cytosolic and nuclear staining. IGCNU was
appreciable in nearly all tumour samples (90%). In all
these cases, the neoplastic cells present in the IGCNU
showed weak (<3%) CCDC6 nuclear stainings similar to
normal spermatogonial cells (Figure 3, middle). In the yolk
salk tumor and in the embrionary carcinomas the immu-
nostaining for CCDC6 was nearly undetectable (Figure 3,
bottom).
In order to evaluate the activation of the DDR machin-
ery in the same set of samples, we investigated the im-
munostaining for pS1981_ATM, the activated form of a
key upstream regulator that controls most DDR events;
the staining for pT68_Chk2, a central mediator of DDR
that resulted barely detectable in IGCNU and in primary
tumours was also analysed (Figure 4). Histone H2AX
phosphorylation, a downstream chromatin modification
linked to the generation of double-strand breaks (DSBs),
showed a certain grade of positivity in normal germ cells
(Figure 4). Such positivity for histone phosphorylation,
visible also in some of the testicular seminomas analysed,
was likely to be due to replicative stress in the sperm-
atocyte population in the different phases of differenti-
ation present in the tumour and healthy tissues, as
already reported [8]. At the end, we checked the expres-
sion of MDC1, recently emerged as an important spatio-
temporal regulator of the genome integrity maintenance
close to the top of the DNA machinery signaling and le-
sion proceeding cascades [25,26]. An aberrant reduction
or a lack of MDC1 has been reported in a significant
proportion of carcinomas supporting its candidacy as a
tumor suppressor [26]. In contrast to carcinomas, almost
no activation or loss has been found in testicular germ
cell tumours [27]. We also found no substantial variation
in the expression of MDC1 among our cases: a definite
nuclear staining for MDC1 was in fact present in the nor-
mal seminiferous tubules (Figure 4), as reported [28], in
the IGCNU (middle part of Figure 4) and in the invasive
seminomas. Next, we confirmed all the observations
we obtained by IHC staining also by Western blot ana-
lysis of 10 primary tissues obtained from a different set
of patients. As shown in the representative samples of
Figure 5, CCDC6 was expressed at very low levels in al-
most all seminomas and was virtually absent in teratocar-
cinomas and in embryonal carcinomas, compared to the
normal samples (Figure 5). Moreover, we investigated theCCDC6 protein expression in the TCam-2 cell line, de-
rived from a human seminoma. By immunoblot analysis,
protein hybridization showed a low expression of CCDC6
in the TCam2 seminoma cells, similar to the primary tu-
mours (Figure 5A). Quantitative real time PCR analysis
showed low levels of transcripts for CCDC6 in these cells,
compared to the expression levels detected in the GC1
cells (Figure 5B), suggesting that the loss of CCDC6 in the
neoplastic seminoma cells might not be dependent on a
post-transcriptional mechanism. Next, in order to investi-
gate the level of activation of the DDR molecules in the
seminoma TCam2 cells, we performed Western Blot
hybridization with specific antibodies against pS1981_ATM
(pATM), pT68_Chk2 (pChk2) and pS139_H2AX (γH2AX)
observing a barely detectable signal, after 1 hour treatment
with 10 μM H2O2 for all these DDR activation markers in
TCam2 cells, compared to the levels observed in the GC1
normal testicular germ cells [18] (Figure 5C).
Figure 4 Immunohistochemical staining for the DDR molecules in seminoma, IGCNU and normal testis. pS1981-ATM, pT68-CHK2, γH2AX
and MDC1 show weak to absent, focal nuclear positivity. Immunostaining for ATM, CHK2 and H2AX shows a strong nuclear reactivity in all the
samples. Magnifications are 250× for pS1981ATM and ATM in seminoma, 200× for CHK2 and γH2AX in normal trestis, 150× for the remaining.
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tumors
To confirm our findings and in order to extend the
CCDC6 expression analysis in a larger set of human tes-
ticular samples, we took advantage of the tissue microarray
(TMA) technique. TMA is a reliable and representative
technology that allows the in situ analysis of tumoural andnormal tissue samples in a high-throughput and internally
controlled format. We screened a total of 87 human tes-
ticular tumours of different histotypes and 10 paired nor-
mal tissues using TMA. In Table 1, the TMA composition
of the tumours derived from the testicular germ cells is
listed. The CCDC6 protein expression was reduced in the
tumours as witnessed by the low signal obtained per single
Figure 5 Analysis of CCDC6 expression in normal human testis and testicular germ cells tumors. (A) 40 ug of total tissue lysates were
resolved on 10% SDS-PAGE transferred onto nitrocellulose filters and western blotted with α-CCDC6 antibody. NT, normal testis; lanes 2–6:
seminomas; lane 7, teratoma; lane 8, embryonal carcinoma; lane 9, TCAM2 seminoma cell line. Anti-actin hybridization is shown as loading
control. The blots are representative of three independent experiments. (B) Top: CCDC6 relative expression in TCAM2 and GC1 cells analysed by
qRT-PCR. Data are the mean +/− SD of three independent experiments. Bottom: CCDC6 expression in the unique TCAM2 seminoma cells and
GC1 Cells. Whole lysates were detected by western blotting with anti-CCDC6 antibody. (C) the activation of the molecules of the DNA Damage
Response were monitored using the anti-pS1981_ATM (pATM), the anti-pT68_Chk2 (pChk2), and the anti-pS139_H2AX (γH2AX). Total ATM, Chk2
and H2AX are shown. Before lysis, the cells have been treated 1 hour with H2O2 (10 μM), and after washing out the hydrogen peroxide the cells
have been left an additional hour before the lysis. Anti-tubulin hybridization is shown as loading control.
Staibano et al. BMC Cancer 2013, 13:433 Page 9 of 12
http://www.biomedcentral.com/1471-2407/13/433cells and by the decreased number of cells/field stained
with the anti-CCDC6 antibody.
In all the testicular seminomas and embryonal carcin-
omas, we observed a low to absent nuclear positivity for
CCDC6 (Figure 4). Together with the CCDC6 protein,
we also assessed the engagement of the DDR machinery
in the same tumours and in their normal counterparts,
when available. Specifically, we investigated the DDR-
signaling cascade at three nodal points: pS1981_ATM,
the activated form of a key upstream regulator that con-
trols most DDR events; pT68_Chk2, a central mediatorof DDR and pS139_H2AX, the chromatin event follow-
ing DSBs. By these markers we observed that DDR ma-
chinery activation resulted virtually absent in the human
testicular tumours analyzed: little evidences of the acti-
vated checkpoint kinases ATM or Chk2 was indeed ob-
served (data not shown), in contrast to some cells that
showed activated pS139_H2AX (Table 1).
Discussion
The incidence of testicular germ-cell cancer, the most
common malignancy in young men, has recently shown
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trend, together with the worrying decline in male repro-
ductive health, and the fascinating biology of the germ
cells and germ-cell tumours (GCTs), have stimulated an
increasing number of studies to better understand the
cellular and molecular biology of reproductions, and the
molecular pathogenesis of testicular cancer [29-32].
The genome locus for CCDC6 is commonly rearranged
in various tumours and, despite the emerging role for
CCDC6 as a tumour suppressor, possibly controlling intra
S-phase [33] and G2/M cell cycle checkpoints and DNA
repair [11], its biology and pathology remain largely unex-
plored. A few CCDC6 somatic mutations have been
reported in some tumours (www.sanger.ac.uk/genetics/
CGP/cosmic), but they are still in need of characterization.
Also, there are no data on the abundance, localization or
cell-type specificity of the CCDC6 protein in human tis-
sues and tumours. The reasons which led us to choose
spermatogenesis and testicular cancer to study CCDC6 in-
clude: (i) that CCDC6 is predicted as downregulated in
germ cell tumours (by the analysis of the ArrayExpress
Archive database), (ii) the occurrence, in the same tissue,
of both mitotic and meiotic cell cycles, (iii) the high fre-
quency of programmed DSBs as an essential part of gen-
etic recombination during meiosis and (iv) the oxidative
DNA damage envisaged as emerging mechanism of car-
cinogenesis in this tissue [5,34].
For the purpose of assessing CCDC6 expression in a
large series of human testicular tumour samples, we
analysed 20 primary tumours by also taking advantage of
the TMA technique, that provides a great opportunity to
easily analyze, store and share IHC data of a large number
of samples [35-37]. Primary tumours and TMA immuno-
staining investigations of CCDC6 expression demon-
strated that CCDC6 is severely downregulated in all the
different testicular tumours analyzed. Moreover, the ana-
lysis of IGCNU, the presumed precursor lesion of germ
cell tumours, showed a barely detectable nuclear staining
for CCDC6, suggesting that CCDC6 loss might represent
an early event during cancer development in the testis.








Seminoma 46 53 39/46 - +/-
7/46 +/- -
Embryonal carcinoma 15 17,1 15/15 - +/-
Mixed carcinoma 20 23 20/20 +/- +/-
Teratoma 5 5,8 2/5 +/- +/-
3/5 - -
Yolk sac tumor 1 1,1 1 /1 - +/-in CCDC6 at mRNA and protein levels in the unique
seminoma TCAM2 cell line reinforces the hypothesis that
the loss of CCDC6 expression might occur as a transcrip-
tional event. Since no fusions or mutations involving
CCDC6 have been reported in testicular cancer, so far, we
cannot rule out the existence of other mechanisms, such
as promoter methylation that could contribute to inacti-
vate CCDC6 in TGCTs. Nevertheless, we can assume that
in different tissues, other than the testis, CCDC6 may be
inactivated or lost by different mechanisms, such as post-
translational modifications, and also at different stages of
tumour development, initiation or progression. Further in-
vestigations are in progress in different tumour histotypes
in order to clarify these critical points.
By analyzing the murine testicular cell population by
IHC and by cell population fractionation, we observed a
specific expression of CCDC6 in the spermatogonial cells.
In contrast, CCDC6 was weakly expressed or undetectable
in the spermatocytes at different stages of meiosis, and vir-
tually negative in the post-meiotic stages of spermatogen-
esis. The progressively decreasing levels of CCDC6 during
the spermatocytic differentiation process could reflect the
different levels of control needed for the mitotically prolif-
erating testicular cells rather than during meiotic recom-
bination where CCDC6 could probably induce inadequate
apoptosis and undermine spermatogenesis.
DNA damage response is emerging as a physiological
anti-cancer barrier in early stages of cancer development
in several types of solid cancer, derived from somatic cells,
as opposed to the exceptional paucity of such constitutive
activation in human testicular germ cell tumours (TGCTs)
[8]. Indeed, we detected low levels of CCDC6 and con-
firmed a very low activation of DDR-controlling molecules
in the testicular germ cells tumours that we analyzed.
Interestingly, complex anti-oxidant defense systems
have been reported in rat and human testes [34,38], while
oxidative DNA damage is emerging as a mechanism of
carcinogenesis [5,39]. Several studies have, in fact, also
documented the presence of high levels of oxidative dam-
age in A-T patients [40]. Recently, the ATM kinase has
been reported to promote anti-oxidant defense and DNA
repair, and, consequently, has been involved in response
to oxidative stress [41].
It has been reported that, in primary testicular germ
cells, the treatment with low doses of H2O2 is associated
with a rise in oxidative stress and an induction of apop-
tosis [24]. H2O2 is a by-product of the cell metabolism
and its cellular levels and maintenance are constantly
under homeostatic regulation. As the major pathway of
cell removal from the testis is through apoptosis, it is rea-
sonable to assume that the redox status may either trigger
or block the apoptotic death program depending on the
severity of the oxidative stress. In this study, we first dem-
onstrated that treatment of the GC1 cells with low doses
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upon H2O2 treatment, the silencing of CCDC6 or the mu-
tation in the recognition site for the ATM kinase in pri-
mary GC1 germ cells increases the rate of survival,
impairs the phosphorylation of histone H2AX on S139, af-
fects ROS production and makes the cells more resistant
to oxidative damage. Since we have previously reported
that CCDC6 could be considered a stress response protein
participating to the control of genome stability [11], we
can hypothesize that CCDC6 loss or impairment could
also represent a mechanism to protect the cells from oxi-
dative stress [9].
Conclusions
In conclusion, our results suggest that the loss of CCDC6
in tumour testes could represent a specific event that
helps testicular germ cell tumours formation. Moreover,
defects in the DDR machinery could account for the bene-
ficial effects of radio and/or chemo-therapy in association
with surgical treatment in these tumours. However, we be-
lieve that a recurrence of the disease, even at low fre-
quency, could be generated by a sub-population of tumor
germ cells still able to activate the DDR. Therefore, we
hypothesize that CCDC6 usage as a marker of cell popula-
tion resistance could eventually favour a personalized
treatment choice.
Additional files
Additional file 1: Figure S1. GC-1 cells were transfected with mission
shCCDC6 or a control non-targeting scrambled sh, after 48h were treated
with H2O2 at different doses (range of 1, 2, 5, 10 and 50 μM) for 30 min
and 1h, as indicated. After washing out the hydrogen peroxide we have
left the cells an additional hour before processing them. 20 ml of
Promega’s CellTiter 96 AQueous One Solution (Promega) were then
dispensed into each well and absorbance at 595nm was measured to
evaluate cell viability. Data reported are the average +/− s.d. of three
independent experiments performed in sextuplicate.
Additional file 2: Figure S2. Densitometric analysis has been
performed by Image J software; the results of three independent
experiments were plotted as percent of the ratio between the CCDC6
and tubulin intensity, respectively, as indicated. Error bars, +/− SD.
P values are shown.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SS and AC designed the experiments. VL, CL, FM, FE and FM performed
most of the experiments. SS, GI and MS performed the immunostainings and
discussed the results. RF, PC and AF provided reagents and insightful
comments on this work. AC analysed the experiments and wrote the
manuscript. All authors reviewed and edited the manuscript drafts and
agreed to the final version of the manuscript.
Acknowledgements
This work was supported by the Associazione Italiana Ricerca sul Cancro
(AIRC n. 4952 to AC), by POR Campania FSE 2007/2013 “CREME Campania
Research In Experimental Medicine”, to CNR-IEOS-UOS Napoli and by the
“Ministero dell’Istruzione, dell’Università e della Ricerca” (MIUR) (PRIN
20072JHN5W_003 to AC). We kindly acknolwledge Professor GiancarloVecchio for his encouragement and support. We are grateful to Dr Mario
Chiariello and to Dr Aniello Cerrato for critical reading of the manuscript and
for helpful discussion. We thank Mario Berardone for artwork. Angela Celetti
is grateful to CNR for the Short Term Mobility Award in 2009.
Author details
1Istituto di Endocrinologia ed Oncologia Sperimentale, CNRz, via S Pansini, 5,
Naples 80131, Italy. 2Dipartimento di Medicina Molecolare e Biotecnologie
Mediche, Università Federico II, Naples, Italy. 3Dipartimento di Scienze
Biomediche Avanzate, Università Federico II, Naples, Italy. 4ISNT G. Pascale,
Naples, Italy. 5Dipartimento di Psicologia, Seconda Università di Napoli,
Caserta 81100, Italy.
Received: 18 April 2013 Accepted: 17 September 2013
Published: 24 September 2013
References
1. Oosterhuis JW, Looijenga LH: Testicular germ-cell tumors in a broader
perspective. Nat Rev Cancer 2005, 5:210–222.
2. Chieffi P: Molecular targets for the treatment of testicular germ cell
tumors. Mini-Rev Med Chem 2007, 7:755–759.
3. Chieffi P, Franco R, Portella G: Molecular and cell biology of testicular
tumors. Int Rev Cell Mol Biol 2009, 278:277–308.
4. Waheeb R, Hofmann MC: Human spermatogonial stem cells: a possible
origin for spermatocytic seminoma. Int J Androl 2011, 34(4 Pt 2):e296–e305.
5. Liu J, Qu W, Kadiiska MB: Role of oxidative stress in cadmium toxicity and
carcinogenesis. Toxicol Appl Pharmacol 2009, 238:209–214.
6. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, et al:
ATM activation in normal human tissues and testicular cancer. Cell Cycle
2005, 4:838–845.
7. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al:
Activation of the DNA damage checkpoint and genomic instability in
human precancerous lesions. Nature 2005, 434:907–913.
8. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J, et al: DNA
damage response in human testes and testicular germ cell tumours:
biology and implications for therapy. Int J Androl 2007, 30:282–291.
9. Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G, et al: H4(D10S170), a
gene frequently rearranged with RET in papillary thyroid carcinomas:
functional characterization. Oncogene 2004, 23:109–121.
10. Merolla F, Pentimalli F, Pacelli R, Vecchio G, Fusco A, et al: Involvement of
H4(D10S170) protein in ATM-dependent response to DNA damage.
Oncogene 2007, 26:6167–6175.
11. Merolla F, Luise C, Muller MT Pacelli R, Fusco A, et al: Loss of CCDC6, the
first identified RET partner gene, affects pH2AX S139 levels and
accelerates mitotic entry upon DNA damage. PLos ONE 2012, 7(5).
e36177.doi:10.1371/journal.pone.0036177
12. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, et al: PTC is a novel
rearranged form of the RET proto-oncogene and is frequently detected
in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557–563.
13. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, et al: RET, ROS1 and ALK
fusions in lung cancer. Nat Med 2012, 18:378–381.
14. Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, et al: H4(D10S170), a
gene frequently rearranged in papillary thyroid carcinoma, is fused to
the platelet-derived growth factor receptor beta gene in atypical chronic
myeloid leukemia with t(5;10)(q33;q22). Blood 2001, 97:3910–3918.
15. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, et al: Fusion of H4/D10S170
to the platelet-derived growth factor receptor beta in BCR-ABL-negative
myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 2000,
60:3592–3598.
16. Puxeddu E, Knauf JA, Sartor MA, Medvedovic M, Moretti S, et al: RET/ PTC-
induced gene expression in thyroid PCCL3 cells reveals early activation
of genes involved in regulation of the immune response. Endocr Relat
Cancer 2005, 12:319–313.
17. Luise C, Celetti A: The genome stability is preserved by a stress response protein:
CCDC6. Germany: Lamberth Academic Publication; 2012. ISBN 978-3-659-14353-3.
18. Hofmann MC, Narisava S, Hess RA, Millán JL: Immortalization of germ cells
and somatic testicular cells using the SV40 large T antigen. Exp Cell Res
1992, 201:417–435.
19. Mizuno Y, Gotoh A, Kamidono S, Kitazawa S: Establishment and
characterization of a new human testicular germ cell tumor cell line
TCam-2. Nippon Hinyokika Gakkai Zasshi 1993, 84:1211–1218.
Staibano et al. BMC Cancer 2013, 13:433 Page 12 of 12
http://www.biomedcentral.com/1471-2407/13/43320. Rossi P, Dolci S, Albanesi C, Grimaldi P, Ricca R, et al: Follicle stimulating
hormone induction of steel factor (SLF) mRNA in mouse Sertoli cells and
stimulation of DNA synthesis in spermatogonia by soluble SLF. Dev Biol
1993, 155:68–74.
21. Fedele M, Franco R, Salvatore G, Paronetto MP, Barbagallo F, et al: PATZ1
gene has a critical role in the spermatogenesis and testicular tumours.
J Pathol 2008, 215:39–47.
22. Esposito F, Boscia F, Franco R, Tornincasa M, Fusco A, et al: Down-
regulation of estrogen receptor-β associates with transcriptional
coregulator PATZ1 delocalization in human testicular seminomas.
J Pathol 2011, 224:110–120.
23. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, et al: HMGA
proteins up-regulate CCNB2 gene in mouse and human pituitary
adenomas. Cancer Res 2009, 69:1844–1850.
24. Maheshwari A, Misro MM, Aggarwal A, Sharma RK, Nandan D: Pathways
involved in testicular germ cell apoptosis induced by H2O2 in vitro.
FEBS J 2009, 276:870–881.
25. Hengartner MO: The biochemistry of apoptosis. Nature 2000, 407:770–776.
26. Stucki M, Jackson SP: gammaH2AX and MDC1: anchoring the DNA-
damage-response machinery to broken chromosomes. DNA Repair 2006,
5:534–543.
27. Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, et al:
DNA damage response mediators MDC1 and 53BP1: constitutive
activation and aberrant loss in breast and lung cancer, but not in
testicular germ cell tumours. Oncogene 2007, 26:7414–7422.
28. Bartek J, Lukas C, Lukas J: Checking on DNA damage in S phase. Nat Rev
Mol Cell Biol 2004, 5:792–804.
29. Andrews PW: Teratocarcinomas and human embryology: pluripotent
human EC cell lines. Review article. APMIS 1998, 106:158–167.
30. Dieckmann K-P, Skakkebñk NE: Carcinoma in situ of the testis: review of
biological and clinical features. Int J Cancer 1999, 83:815–822.
31. Grigor KM, Wylie CC: The origin and biology of CIS cells: general
discussion. APMIS 1998, 106:221–224.
32. Skakkebaẽk NE, Berthelsen JG, Giwercman A, Müller J: Carcinoma-in-situ of
the testis: possible origin from gonocytes and precursor of all types of
germ cell tumours except spermatocytoma. Int J Androl 1987, 10:19–28.
33. Thanasopoulou A, Stravopodis DJ, Dimas KS, Schwaller J, Anastasiadou E:
Loss of CCDC6 affects cell cycle through impaired intra-S-phase
checkpoint control. PLoS One 2012, 7:e31007. Epub 2012 Feb 17.
34. Bauché F, Fouchard MH, Jégou B: Antioxidant system in rat testicular cells.
FEBS Lett 1994, 349:392–396.
35. Wan WH, Fortuna MB, Furmanski P: A rapid and efficient method for
testing immunohistochemical reactivity of monoclonal antibodies
against multiple tissue samples simultaneously. J Immunol Methods 1987,
103:121–129.
36. Kononen J, Bubendorf L, KallioniemiA BM, Schraml P, et al: Tissue
microarrays for high-throughput molecular profiling of tumor
specimens. Nat Med 1998, 4:844–847.
37. Mascolo M, Ilardi G, Merolla F, Russo D, Vecchione ML, et al: Tissue
Microarray-Based Evaluation of Chromatin Assembly Factor-1 (CAF-1)/
p60 as Tumour Prognostic Marker. Int J Mol Sci 2012, 13:11044–11062.
38. Hsia KT, Millar MR, King S, Selfridge J, Redhead NJ, et al: DNA repair gene
Ercc1 is essential for normal spermatogenesis and oogenesis and for
functional integrity of germ cell DNA in the mouse. Development 2003,
130:369–378.
39. Visconti R, Grieco D: New insights on oxidative stress in cancer. Curr Opin
Drug Discov Devel 2009, 12:240–245.
40. Russo I, Cosentino C, Del Giudice E, Broccoletti T, Amorosi S, et al: In ataxia-
teleangiectasia betamethasone response is inversely correlated to
cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol
2009, 16:755–759.
41. Cosentino C, Grieco D, Costanzo V: ATM activates the pentose phosphate
pathway promoting anti-oxidant defence and DNA repair. EMBO J 2011,
30:546–555.
doi:10.1186/1471-2407-13-433
Cite this article as: Staibano et al.: Critical role of CCDC6 in the
neoplastic growth of testicular germ cell tumors. BMC Cancer
2013 13:433.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
